Torchlight Energy Resources Inc. (NASDAQ: TRCH) shares are -57.01% down in the year-to-date (YTD) period and have moved 5.42% or $0.02 higher in the latest trading session. However, stock’s trailing 12-month performance remains nearly +15.03% lower. Comparatively, the stock is -69.97% down YTD and -7.97% over the trailing 3-month period. If we look at the shorter duration, its week performance is 6.45% and 0.58% over the month.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
1 analysts offering the recommendations for the stock have a consensus rating of 3.00 to suggest that the TRCH stock is a “Hold. 0 of the 1 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 0 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $0.33. The forecasts give the Torchlight Energy Resources Inc. stock a price target range of $2.70 on the higher side while at least one analyst think the stock could plunge to a low of $2.70. The two limits represent an upside potential of 87.78% or 87.78%.
Analysts estimate the earnings to decrease -800.00% in the current quarter to $0, up from the -$0.02 reported in the same quarter a year ago. Wall Street estimates earnings per share to be at an average of $0 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 0 over the last 12 months, while SEC filings reveal that there have been 0 insider sales over the same period. Insiders have purchases 0 shares while those sold by company executives and officers stand at 0. The last 3 months have seen insiders trade a total of 0 and 0 in purchases and sales respectively.
Aptose Biosciences Inc. (NASDAQ:APTO), on the other hand, is trading around $5.47 with a market cap of $441.98M and analyst research firms have a positive stance on its shares. Analysts predict that the stock will reach $4.72 and spell out a less modest performance – a -15.89% return. Some analysts are even forecasting -$0.86 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Aptose Biosciences Inc. (APTO) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
APTO’s operating expenses over the recent quarter were at -$15.75 million. This represented a 199.18% of the company’s total revenues which amounted $15.88 million. With this in place, we can see that the company’s diluted EPS declined -$0.21 on the year-over-year period, shrinking to -$0.13 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Dec 2017), the total assets figure advanced to $85.32 million from $92.56 million over the previous quarter. Short term investments amounted to $28.61 million while total current assets were at $83.86 million. The cash flow from operating activities totaled -$15.25 million, significantly lower than the -$10.14 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$15.31 million.
Insiders have transacted a total of 16 times at Aptose Biosciences Inc. over the last 6 months, with insider purchases undertaken 9 times and accounting for 670,000 shares. Insider sales totaled 393,394 shares over the same period, with these deals completed in 7 transactions. Looking at these numbers, we realize that net purchases over that period are 2.0 shares. Insiders now hold a total of 6.43M shares after the latest sales, with 18.10% net shares purchased.
Insiders own 20.40% of the company shares, while shares held by institutions stand at 35.10% with a share float percentage of 64.23M. Investors are also buoyed by the number of investors in a company, with Aptose Biosciences Inc. having a total of 67 institutions that hold shares in the company.